Related Experiment Video
Updated: Feb 24, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
VKH-Like Syndrome in a Patient on Tofacitinib
Jessica H Tran1, Hamid Hosseini1, Edmund Tsui2
1Retina Division, Jules Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Tofacitinib may cause Vogt-Koyanagi-Harada (VKH)-like syndrome, leading to serous retinal detachments and choroidal issues. Discontinuation of the drug resulted in symptom resolution, suggesting a drug-induced etiology.
Area of Science:
- Ophthalmology
- Rheumatology
- Pharmacology
Background:
- Vogt-Koyanagi-Harada (VKH) syndrome is a rare autoimmune disorder affecting the eyes, central nervous system, and skin.
- Tofacitinib is a Janus kinase inhibitor used to treat autoimmune diseases.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Chronic Kidney Disease II: Clinical Manifestations
Hypersensitivity Reactions: Immune-Complex Reactions
The JAK-STAT Signaling Pathway
Drug toxicity: Idiosyncratic Reactions
TGF - β Signaling Pathway

